Back to Search Start Over

Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.

Authors :
Zhang HF
Hughes CS
Li W
He JZ
Surdez D
El-Naggar AM
Cheng H
Prudova A
Delaidelli A
Negri GL
Li X
Ørum-Madsen MS
Lizardo MM
Oo HZ
Colborne S
Shyp T
Scopim-Ribeiro R
Hammond CA
Dhez AC
Langman S
Lim JKM
Kung SHY
Li A
Steino A
Daugaard M
Parker SJ
Geltink RIK
Orentas RJ
Xu LY
Morin GB
Delattre O
Dimitrov DS
Sorensen PH
Source :
Cancer discovery [Cancer Discov] 2021 Nov; Vol. 11 (11), pp. 2884-2903. Date of Electronic Publication: 2021 May 21.
Publication Year :
2021

Abstract

Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system X <subscript>c</subscript> <superscript>-</superscript> transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. SIGNIFICANCE: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy. See related commentary by Yoon and DeNicola, p. 2679 . This article is highlighted in the In This Issue feature, p. 2659 .<br /> (©2021 The Authors; Published by the American Association for Cancer Research.)

Details

Language :
English
ISSN :
2159-8290
Volume :
11
Issue :
11
Database :
MEDLINE
Journal :
Cancer discovery
Publication Type :
Academic Journal
Accession number :
34021002
Full Text :
https://doi.org/10.1158/2159-8290.CD-20-1690